Treviamet Xr 50 plus 1000mg Tablet

Description

Treviamet Xr 50 plus1000mg Tablet

Treviamet Xr 50 plus 1000mg Tablet (Sitagliptin + Metformin HCl) tablets contain two oral antidiabetic medications used in the management of type 2 diabetes; Treviamet Xr 50 plus 1000mg Tablet (extended release). Treviamet Xr 50 plus 1000mg Tablet is an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzymes. Chemically, it is 7-[(3R)-3- amino -1-oxo -4-(2,4,5-trifluorophenyl)butyl] -5,6,7,8 -tetrahydro -3-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyrazine phosphate (1:1) monohydrate.Treviamet Xr 50 plus 1000mg Tablet molecular formula is C16H15F6N5O•H3PO4•H2O. Lactic acidosis Metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence and abdominal pain. Laboratory abnormalities of Treviamet Xr 50 plus 1000mg Tablet included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio and metformin plasma levels generally >5 mcg/mL. If lactic acidosis is suspected, discontinue Treviamet Xr 50 plus 1000mg Tablet and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. Pancreatitis After initiation of Treviamet Xr 50 plus 1000mg Tablet, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Treviamet Xr 50 plus 1000mg Tablet should promptly be discontinued and appropriate management should be initiated.

Uses

This medicine is used for treating type 2 diabetes (condition characterized by elevated glucose levels) that is inadequately controlled by metformin, diet and exercise. It is used for treating diabetes type 2 along with metformin or a glitazone when patients respond inadequately to diet changes, exercise and either metformin or glitazine, or in combination with sulphonylureas in patients contraindicated for metformin, and for patients that do not respond adequately to sulphonylureas alone.

 Side effect :

The patients administered with this medicine may experience pancreatitis (inflammation of pancreas), allergic reactions, Stevens-Jhonson Syndrome (allergic reaction), Hypoglycemia , bullous pemphigoid (large fluid-filled blisters), osteoarthritis (weak bones), upper respiratory tract infections, flatulence, swelling, and influenza .

 When not use :

Known hypersensitivity to sitagliptin and metformin HCl or to any of excipient of the product. • Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels ≥133 micromol/L , or abnormal creatinine clearance